Anthropic has acquired the single‑person biotech firm Mithril Medicine, advancing a candidate therapy for a rare form of muscular dystrophy into mouse studies within 18 months and achieving preliminary positive results. Simultaneously, it has established deep collaborations with six leading institutions, including BMS and Generate Biomedicines, with Claude making quantifiable progress across molecular design, clinical planning, and other key areas—potentially enabling the initiation of human clinical trials as early as late 2028.
$Anthropic (ANT.US)$It is extending AI capabilities from conversational tools to the core processes of drug discovery.
According to the latest update posted on Anthropic's official website on October 27, the company's life sciences team has established in-depth research collaborations with six institutions and acquired Mithril Medicine, a biotechnology firm operated by a single individual, thereby entering the drug‑development arena directly.
Anthropic stated that its AI model, Claude, has demonstrated quantifiable efficiency gains across multiple stages, including molecular design, manufacturing‑document review, regulatory submissions, and clinical‑trial planning, with some early data already made public.
The company stated clearly that it plans to "significantly scale up" the aforementioned work and will continue to extend Claude's involvement through to the human clinical trial phase.
Acquiring a "one-person pharmaceutical company" and personally entering the pharmaceutical business.
$Anthropic (ANT.US)$The most notable move this time was the acquisition of Mithril Medicine, a micro‑biotechnology company independently operated by its founder, Cody Tranbarger.
Mithril Medicine focuses on research into the treatment of two rare forms of childhood muscular dystrophy. Previously, Tranbarger relied on Claude to coordinate contracts, logistics, and experimental arrangements with 11 external laboratories, entrusting Claude with a significant portion of the company's operational tasks.
The result is that, in less than 18 months, Mithril Medicine advanced one of its candidate therapies for muscular dystrophy from the conceptual stage to the mouse‑level experimental phase, achieving preliminary positive results.
Tranbarger has now joined Anthropic to continue advancing the aforementioned research and plans to launch several new projects. Anthropic stated that, if the candidate drug continues to demonstrate favorable results, it could be ready to initiate human clinical trials as early as late 2028.
Six major partners, covering the entire R&D value chain.
In addition to independent research and development,$Anthropic (ANT.US)$Over the past few months, we have established collaborations with six institutions, spanning multiple stages of drug development—from early-stage discovery to clinical planning.
Generate Biomedicines: CAR-T Therapy Engineering
Generate Biomedicines is working to expand CAR‑T cell therapy from hematologic malignancies to solid tumors. Six scientists have devised a new design for the key genetic sequence that encodes the therapy's receptor, using Claude Code. One of these designs is approximately 70% shorter than the standard version; laboratory tests show that the engineered immune cells produce about ten times as many receptors, exhibit greater tumor‑killing efficiency, and remain activated for a longer duration.
Divergence Labs: A New Therapy for Food Allergies
Divergence Labs is developing a novel drug for food allergies, aiming to completely remove IgE molecules from immune cells rather than merely neutralizing free IgE in the bloodstream. Claude translated the research objectives into detailed design specifications and, within approximately one month, autonomously generated roughly 35,000 antibody design candidates. In early screening, researchers identified effective candidates targeting two functional "arms": three that bind to IgE and twenty that strip IgE from immune cells, with three of these outperforming existing standard‑of‑care therapies.
BigHat Biosciences: Molecular Optimization
BigHat Biosciences integrates AI with automated laboratory workflows to optimize drug‑candidate molecules. Over roughly 10 weeks, the team screened approximately 1,010 molecular variants. Midway through, Claude collaborated with the researchers to re‑analyze the raw data, refining the evaluation metrics and experimental protocols. The final results showed that the top‑performing variant exhibited more than a tenfold increase in binding affinity, the cancer‑targeting candidate demonstrated an 18°C improvement in thermal stability, and another candidate's aggregation rate was reduced by over a factor of 100.
Enveda: Document Review and Regulatory Filing
Enveda's manufacturing chemists previously spent as much as 75% of their time on document processing. Enveda developed a system that integrates manufacturing documents with Claude to automatically flag potential issues. In testing on 1,061 pages of documentation, Claude identified all 11 issues detected by human reviewers and additionally flagged 7 more that had been overlooked by humans. Overall manual review time was reduced from over 25 hours to less than 3 hours, a decrease of 89%.
In addition, Claude drafted two significant regulatory documents. One of them took just four hours to prepare, whereas performing a similar task manually would typically require about three months.
The Column Group: Building an "AI-Native" Pharmaceutical Company
The Column Group (TCG) is collaborating with Anthropic to explore whether it can reduce the time and cost of drug discovery, thereby encouraging investors to back more high‑risk innovative projects. TCG is establishing a new company, Pleiades, which plans to run a larger number of more complex drug‑development programs with small teams. To date, Pleiades has developed its first Claude‑powered skill module for assessing the research value of drug targets, having already completed evaluations across 45 target–disease pairings.
Bristol Myers Squibb: Clinical Trial Planning
BMS is the newest of the six partner organizations. BMS is leveraging Claude to analyze trial protocols for early‑stage clinical drugs and to assess the likelihood of trial success.
Michael Pourdehnad, Senior Vice President of Early Clinical Development and Head of Hematologic Oncology and Cell Therapy at BMS, stated: "We use Claude to analyze proprietary data, design clinical study protocols, and assess the likelihood of study success during the clinical trial phase. With just a single prompt, Claude generates a comprehensive preliminary analysis that helps us evaluate various development strategies—work that would typically take several days if performed manually."
The two parties plan to expand the scope of their collaboration in 2027 and further assess the potential of AI in enhancing the success rate of early-stage drug development.
Strategic Layout: Open Platform, Expanding Coverage
$Anthropic (ANT.US)$It stated that the aforementioned collaborative research is merely part of its life sciences strategy, with the goal of making Claude's capabilities accessible to a broader range of drug‑development organizations.
To this end, Anthropic has launched a series of complementary initiatives:
Claude Science: An AI Workbench for Researchers;
Life Sciences Verification Program: Allows trusted entities to use the most powerful models under more relaxed security constraints, thereby supporting legitimate biological research.
Open Call for Visiting Researchers: Proposals are invited from research teams seeking to leverage Claude for addressing critical challenges in drug discovery and other fields.
At the same time, Claude usage credits are provided to life science researchers.
$Anthropic (ANT.US)$It was emphasized that, at present, all research remains in its early stages, with most studies yet to enter human clinical trials. The company plans to continue expanding Claude's involvement into the clinical phase as its drug programs advance.
Edited by melody